ISRN Chromatography

Volume 2013 (2013), Article ID 328157, 8 pages

http://dx.doi.org/10.1155/2013/328157

Research Article

Cefpodoxime Proxetil: A New Stability Indicating RP-HPLC Method

Ceema Mathew,1,2 M. Ajitha,² and P. R. Sathesh Babu¹

¹Gokaraju Rangaraju College of Pharmacy, Osmania University, Bachupally, Hyderabad 500 090, India

²Jawaharlal Nehru Technological University, Hyderabad 500 085, India

Received 24 April 2013; Accepted 29 May 2013

Academic Editors: J. A. P. Coelho, B. Fernandez De Simon, and M. Hassan

Copyright © 2013 Ceema Mathew et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

The present work describes the development of a sensitive and economic stability indicating high performance liquid chromatographic (HPLC) method for the determination of cefpodoxime proxetil (CP) as bulk drug and as pharmaceutical formulation. Both R and S isomers of the drug were separated using Phenomenex ( mm, 5 μm particle size) ODS column with a flow rate of 1 mL min⁻¹ and an SPD 20 A UV detector to monitor the eluate at 252 nm. The isocratic method used a mobile phase consisting of methanol and phosphate buffer of pH 4.0 in the ratio 65 : 35. The linear regression analysis data for the calibration plots showed good linear relationship with in the working concentration range of 5–100 μg mL⁻¹. The LOD and LOQ were 53 and 160 ng mL⁻¹, respectively. CP was subjected to stress degradation using acid, alkali, hydrogen peroxide, dry heat, wet heat, and UV light. The standard drug peaks were well resolved from the degradation products’ peaks with significantly different retention time (Rt), and the resolution factor for the R and S isomers of CP was found to be greater than 2.

1. Introduction

Stability indicating methods are the quantitative analytical methods that are based on the characteristic structural, chemical, or biological properties of each active ingredient of a drug product and that will distinguish each active ingredient from its degradation products so that the active ingredient content can be accurately measured [1]. The International Conference on Harmonization (ICH) guideline entitled “Stability Testing of New Drug Substances and Products” requires that stress testing be carried out to elucidate the inherent stability characteristics of the active substance [2]. Acidic, alkaline, oxidative, and photolytic stabilities are required. An ideal stability indicating method is the one that quantifies the standard drug alone and also resolves it from its degradation products [3].

Stability indicating method is an analytical procedure that is capable of discriminating between the major active pharmaceutical ingredient (API) and any degradation (decomposition) product(s) formed under defined storage conditions during the stability evaluation period [4]. Cefpodoxime proxetil (CP) is a prodrug that is deesterified in vivo to its active metabolite, cefpodoxime, to exhibit antibiotic activity [5–9]. The structure of CP is given in Figure 1. It is active against most Gram positive and Gram negative organisms. It is commonly used in the treatment of a variety of infections of skin, respiratory tract, urinary tract, and systemic infections and also to treat acute otitis media, pharyngitis, and sinusitis. CP is supplied as a racemic mixture of two enantiomers R and S in a ratio of about 1 : 1 [7]. There are some reported methods for the quantification of cefpodoxime proxetil alone and in combination with potassium clavulanate [10–14], and there are a few stability indicating assay methods and methods for related substances [15–19].

Figure 1: Structure of Cefpodoxime proxetil (CP).

In many of the HPLC methods, acetonitrile is used as the organic phase. It is a toxic chemical as it can cause environmental pollution and health hazards to human beings and animals [20]. As per the available literature, the mobile phase for CP is either acetonitrile and buffer or acetonitrile, methanol, and buffer in different ratios. In an attempt to practice green chemistry, in the present investigation, it is substituted with less toxic and less expensive methanol for the development of a cost effective and safer analytical methodology that can quantify CP in pharmaceutical dosage forms and resolve the pure drug from its degradation products.

2. Experimental

2.1. Materials and Reagents

Cefpodoxime proxetil API (with a purity of 99.30% which contains both R and S isomers) was available as a gift sample from See Gee Pharmaceuticals Pvt. Ltd., Puducherry. Methanol, disodium hydrogen phosphate, and potassium dihydrogen phosphate were purchased from S.D Fine Chemicals (Mumbai, India) and were of HPLC grade. Hydrochloric acid, sodium hydroxide pellets, hydrogen peroxide, and orthophosphoric acid were purchased from S.D Fine Chemicals (Mumbai, India) and were of A.R grade. Purified water was prepared in-house by distillation of water in triplicate followed by filtration through filter paper of 0.45 μm pore size and 47 mm diameter.

2.2. HPLC Instrumentation

The HPLC system consists of a Shimadzu LC 20 AD binary pump and SPD 20 A UV detector. The column consists of Phenomenex (250 mm length, 4.6 mm internal diameter, and 5 μm particle size) ODS. LC Solution software was used for data acquisition. Sample injection was done by Rheodyne manual injector.

2.3. Chromatographic Conditions and Mobile Phase Preparation

Chromatographic separation was achieved using Phenomenex ODS column. The LC system was operated isocratically using a mobile phase consisting of a mixture of methanol and phosphate buffer of pH 4.0 (prepared with 5.04 g of disodium hydrogen phosphate and 3.01 g potassium dihydrogen phosphate dissolved in 1000 mL of triple distilled water and the pH was adjusted to 4.0 using orthophosphoric acid) in the ratio of 65 : 35 as the mobile phase at a flow rate of 1.0 mL/min at room temperature. The injection volume was 20 μL for both standard and sample. The UV detector was set at 252 nm, and the peak areas were integrated automatically using LC Solution software. Peak identity was confirmed by retention time comparison.

2.4. Procedures

2.4.1. Preparation of Cefpodoxime Proxetil Standard

The stock solution of CP was prepared by weighing 10 mg of the reference substance and transferring it to a 10 mL volumetric flask, diluting to 10 mL with methanol (1000 μg/mL). The working standard solution (100 μg/mL) was obtained by dilution of the stock solution using mobile phase.

2.4.2. Preparation of Sample Solution

Two brands of cefpodoxime tablets (Cefoact—100 mg, Cepodem—100 mg) were purchased from a local pharmacy. Twenty tablets of each brand were accurately weighed and crushed to fine powder separately. A quantity of powder equivalent to 25 mg of CP was transferred to a 25 mL volumetric flask and added 10 mL of methanol, kept in an ultrasonic bath for 10 min and made up to the volume with methanol and filtered.

2.5. Validation Study

The developed method was validated as per ICH guidelines using CP with respect to the following parameters: accuracy, precision, LOD, LOQ, specificity, robustness, stability, and system suitability.

2.5.1. Linearity

For testing linearity, seven calibration standards were prepared in the range of 5 to 100 μg/mL (5, 10, 20, 40, 60, 80, and 100 μg/mL). Standard curve was obtained by plotting peak area against concentration, and the evaluation of linearity was done by linear regression analysis using least square method.

2.5.2. Limit of Detection and Limit of Quantitation

Normally, limit of detection (LOD) and limit of quantitation (LOQ) are estimated at a signal to noise ratio of 3 : 1 and 10 : 1, respectively. LOD and LOQ were calculated using (1) and (2), respectively. The theoretical values were confirmed practically by injecting dilute solutions of known concentration.

Consider

where SD is the standard deviation of the area of lowest concentration, and is the slope of the calibration graph.

2.5.3. Specificity

Specificity is the ability of a method to measure analytical response in presence of its potential impurities. Specificity of the method was carried out by the deliberate degradation of the drug by oxidation, heat, hydrolysis (acidic, alkaline, neutral), and photolysis, followed by its analysis using the developed method.

2.5.4. Robustness

Experimental conditions were deliberately altered, and resolution of CP from its degradation products was noticed, in order to determine the robustness. From the different experimental conditions such as flow rate (1.0 mL/min), lambda max (252 nm), and percentage of methanol (65), each selected factor was changed at three levels (−1, 0, and +1). One factor was changed at a time to study the impact of the change in the experimental conditions on the assay results. Difference in the peak area and the retention time were noted at each change in the analytical parameters.

2.5.5. Stability of Sample Solution

Sample solution was prepared and analysed by the HPLC instrument using fresh mobile phase at different time intervals (0 h, 8 h, and 24 h).

2.5.6. Accuracy

Accuracy of the developed method was assessed in triplicate at three concentrations (40, 60, and 80 μg/mL). The percentage recovery was calculated from the linear regression equation obtained in the linearity studies.

2.5.7. Precision

The precision of the analytical method was evaluated by the determination of the repeatability of the method (intraday precision) and intermediate precision (interday precision) of the sample solutions. Repeatability was calculated by assaying six samples prepared on the same day. Intermediate precision was calculated by assaying 3 days. The relative standard deviation of the area of peaks was calculated.

3. Results and Discussion

3.1. Optimization of Chromatographic Condition

The chromatographic conditions were optimized with a view to obtain symmetrical peaks with good resolution between the R and S optical isomers of cefpodoxime proxetil. At the same time, these peaks should be well separated from the degradation peaks so that they can be quantified even in the presence of degradants. Separation was achieved using a mobile phase consisting of methanol and phosphate buffer of pH 4.0 (pH was adjusted to 4.0 with o-phosphoric acid) in the ratio of 65 : 35 by an isocratic profile, pumped at a flow rate of 1 mL min⁻¹. The eluent was monitored using UV detector at a wavelength of 252 nm. The column was maintained at ambient temperature with an injection volume of 20 μL.

3.2. Limit of Detection and Limit of Quantitation

Concentrations of LOD and LOQ were found to be 53 and 160 ng/mL, respectively.

3.3. Linearity

The linearity graph is given in Figure 2(b), and the chromatograms of the different concentrations are shown as an overlay chromatogram in Figure 2(c).

(a)

(b)

(c)

Figure 2: (a) Chromatogram of CP standard 100 μg mL⁻¹. (b) Linearity graph of CP (5, 10, 20, 40, 60, 80, and 100 μg mL⁻¹). (c) Overlay chromatogram of CP (5, 10, 20, 40, 60, 80, and 100 μg mL⁻¹).

The regression equation for the graph is , and the correlation coefficient is 0.9999 showing excellent correlation between the area and the concentration.

3.4. Stability of Sample Solution

The drug was found to be stable in the mobile phase. This was proved by injecting the standard solution at 0, 8, and 24 h after preparation which showed the absence of any extra peaks due to degradation, and there was not much change in the drug peak area (% RSD = 1.19) (Table 1).

Table 1: Stability of sample solution.

Concentration of std. (μg/mL)
Postpreparation time in h
Peak area

100
0
5329310

100
8
5239298

100
24
5361394

% RSD
1.19

3.5. Precision

The percentage relative standard deviation (% RSD) of the area of CP during intraday study was found to be less than 0.4 and for interday study was found to be less than 1.1, which indicated a good precision of the method (Table 2).

Table 2: Intra- and interday precision.

Con. (µg mL⁻¹)
Intraday precisiona
Interday precisionb

Mean con.
SD
% RSD
Mean con.
SD
% RSD

40.0
40.60
0.072
0.178
40.55
0.405
1.000

60.0
60.43
0.300
0.496
60.73
0.130
0.215

80.0
80.33
0.154
0.192
80.37
0.346
0.431

aMean concentration of six trials. bMean concentration of nine trials.

3.6. Accuracy

The quantitative recovery of CP achieved ranged from 100.24 to 102.25% with a low % RSD value. The results of the recovery experiments done at 3 concentration levels and the % RSD values are given in Table 3.

Table 3: Recovery studies.

Excess drug added to analyte (%)
Drug content in µg mL⁻¹
Recovery (%)
% RSD

Theoretical
Practicala

0
20
20.49
102.46
0.687

16
36
36.08
100.236
0.705

20
40
40.90
102.253
0.165

24
44
44.90
102.041
0.212

aMean concentration of six trials.

3.7. Analysis of the Marketed Formulation

The validated method was applied for the assay of CP in 2 brands of cefpodoxime tablets (Cefoact—100 mg, Cepodem—100 mg) (Table 4). Due to the absence of extra peaks in the chromatogram, it can be concluded that there was no interference from the excipients in the formulations.

Table 4: Analysis of the marketed formulation.

Formulation
Labelled amount
Amount found ± SDa
% RSD
% Assay

Tablet Cefoact
100 mg per tablet
101.04 ± 0.84
0.415
101.04

Tablet Cepodem
100 mg per tablet
101.78 ± 0.06
0.027
101.77

aMean concentration of three trials.

3.8. Robustness

The results in the robustness study, as shown in Table 5, indicated that the results are not much affected by the small variations in the selected parameters.

Table 5: Robustness evaluation.a

Factor
Level
Retention time (Rt) for both isomers of CP (min)
Total area for both isomers

(A) Flow rate (mL min⁻¹)

0.95
−1
7.212
8.122
5280908

1
0
7.066
7.927
5239656

1.05
+1
6.99
7.836
5272832

Mean ± SD ( = 3)
7.089 ± 0.113
7.962 ± 0.146
5264465 ± 21861

(B) Percentage of methanol in mobile phase

64
−1
7.133
8.01
5339448

65
0
7.066
7.927
5239656

66
+1
6.911
7.82
5311649

Mean ± SD (n = 3)
7.037 ± 0.114
7.934 ± 0.099
5296917.67 ± 51501

(C) Wavelength of measurement

251
−1
7.068
7.932
5256020

252
0
7.066
7.927
5239656

253
+1
7.095
7.912
5369302

Mean ± SD ( = 3)
7.0763 ± 0.016
7.924 ± 0.010
5288326 ± 70603

aMean values of six trials.

3.9. Specificity

In order to check the specificity of the proposed method, degradation studies were carried out by using acidic, basic, photolytic, oxidative, and thermal conditions. Cefpodoxime proxetil active pharmaceutical ingredient (API) powder was stressed under various conditions to conduct forced degradation studies. Intentional degradation was performed by subjecting it to various stress conditions of acidic (1 N HCl), basic (0.1 N NaOH), neutral (water), oxidative (3% H₂O₂), thermal (heated at 105°C), and photolytic degradation to evaluate the ability of the proposed method to separate CP from its degradation products. Chromatogram of CP, along with the degradation products under various stress conditions, is shown in Figures 3(a) to 3(f).

(a)

(b)

(c)

(d)

(e)

(f)

Figure 3: (a) Chromatogram for alkaline (0.1 N NaOH) degradation. (b) Chromatogram for dry heat degradation. (c) Chromatogram for hydrolytic degradation. (d) Chromatogram for photolytic degradation. (e) Chromatogram for oxidative degradation. (f) Chromatogram for acidic (1 N HCl) degradation.

The degradation kinetics of CP was performed by extending the stress degradation to various time intervals for acidic, alkaline, and oxidative stress, the data of which is given in Tables 6, 7, and 8 as the residual drug (%) in comparison with the zero time sample concentration, and the corresponding graphs are given in Figures 4(a) to 4(c). The graphs clearly indicate that the drug is highly susceptible to alkaline degradation (Figure 4(b)) and it is almost completely degraded within 5 min, after which there is no sample peak. It is further confirmed by the short half-life of 33.10 sec for alkaline degradation. By plotting the logarithm of the drug concentration versus time, a straight line is obtained which indicates that the degradation reactions are of first order. The degradation rate constant and half-life are calculated and are given in Table 9.

Table 6: Residual drug (%) after acidic degradation ( = 3).

Time in h
Residual drug (%) ± SD

0
100 ± 0

24
84.21 ± 2.52

48
82.49 ± 1.83

72
77.25 ± 2.11

96
72.07 ± 0.20

Table 7: Residual drug (%) after alkaline degradation ( = 3).

Time in min
Residual drug (%) ± SD

0
100 ± 0

1
20.17 ± 0.29

2
14.90 ± 0.34

3
2.67 ± 0.15

4
1.87 ± 0.052

Table 8: Residual drug (%) after oxidative degradation ( = 3).

Time in h
Residual drug (%) ± SD

0
100 ± 0

24
62.34 ± 0.12

48
30.62 ± 2.33

72
12.84 ± 0.22

Table 9: Degradation rate constant and half-life.

Sl. no.
Stress condition
Rate constant
Half-life

(1)
Alkaline (0.1 N)
0.021 sec⁻¹
33.10 sec

(2)
Oxidative (3% v/v H₂O₂)
0.023 h⁻¹
29.96 h

(3)
Acidic (1 N)
0.0029 h⁻¹
302.18 h

(a)

(b)

(c)

Figure 4: Kinetics of degradation plotted as residual drug (%) ± SD versus time for (a) acidic degradation, (b) alkaline degradation, and (c) oxidative degradation.

4. Conclusion

An economic stability indicating HPLC method has been developed and validated for the determination of CP in API and different pharmaceutical formulations. The method is accurate, precise, and specific and also has the ability to analyse the drug in presence of its degradation products, and it can be employed as a stability indicating assay. The drug peak was well separated from degradation products’ peaks. The most interesting fact is that the method could separate the R and S isomers without the use of a chiral column or a chiral selector. On comparing the stability of the drug under different stresses, it had undergone faster degradation in alkaline condition, as the drug was almost completely degraded within 4 min and then in oxidative condition. In acidic media, the drug was comparatively stable.

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgments

The authors wish to thank the principal, Professor C. V. S. Subrahmanyam, and the management of Gokaraju Rangaraju College of Pharmacy, Bachupally, Hyderabad, for wholeheartedly supporting this work.

References

Guidelines for Submitting Documentation for the Stability of Human Drugs and Biologics, Food and Drug Administration, Rockvillae, Md, USA, 1987.

“Stability testing of new drug substances and products Q1A,” in Proceedings of the International Conference on Harmonization, Geneva, Switzerland, 1993.

M. Bakshi and S. Singh, “Development of validated stability-indicating assay methods—critical review,” Journal of Pharmaceutical and Biomedical Analysis, vol. 28, no. 6, pp. 1011–1040, 2002.

J. T. Carstensen and C. T. Rhodes, “Development and validation of HPLC stability indicating assays,” in Drug Stability—Principles and Practices, p. 331, Marcel Dekker, New York, NY, USA, 3rd edition, 2005.

M. T. Borin, “A review of the pharmacokinetics of cefpodoxime proxetil,” Drugs, vol. 42, supplement 3, pp. 13–21, 1991.

E. Bergogne-Berezin, “Cefpodoxime in upper respiratory tract infections,” Drugs, vol. 42, no. 3, pp. 25–33, 1991.

A. M. Geddes, “Cefpodoxime proxetil in the treatment of lower respiratory tract infections,” Drugs, vol. 42, supplement 3, pp. 34–40, 1991.

V. K. Kakumanu, V. Arora, and A. K. Bansal, “Investigation on physicochemical and biological differences of cefpodoxime proxetil enantiomers,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 64, no. 2, pp. 255–259, 2006.

E. C. Chocas, C. M. Paap, and P. J. Godley, “Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin,” Annals of Pharmacotherapy, vol. 27, no. 11, pp. 1369–1377, 1993.

F. Camus, A. Deslandes, L. Harcouet, and R. Farinotti, “High-performance liquid chromatographic method for the determination of cefpodoxime levels in plasma and sinus mucosa,” Journal of Chromatography B, vol. 656, no. 2, pp. 383–388, 1994.

V. K. Kakumanu, V. K. Arora, and A. K. Bansal, “Development and validation of isomer specific RP-HPLC method for quantification of cefpodoxime proxetil,” Journal of Chromatography B, vol. 835, no. 1-2, pp. 16–20, 2006.

M. J. Lovdahl, K. E. Reher, H. Q. Russlie, and D. M. Canafax, “Determination of cefpodoxime levels in chinchilla middle ear fluid and plasma by high-performance liquid chromatography,” Journal of Chromatography B, vol. 653, no. 2, pp. 227–232, 1994.

S. Malathi, R. N. Dubey, and R. Venkatnarayanan, “Simultaneous RP-HPLC estimation of cefpodoxime proxetil and clavulanic acid in tablets,” Indian Journal of Pharmaceutical Sciences, vol. 71, no. 1, pp. 102–105, 2009.

F. Molina, F. Jehl, C. Gallion, F. Penner, and H. Monteil, “Determination of the third generation oral cephalosporin cefpodoxime in biological fluids by high-speed high-performance liquid chromatography,” Journal of Chromatography B, vol. 563, no. 1, pp. 205–210, 1991.

G. Patel and S. Rajput, “Stress degradation studies on cefpodoxime proxetil and development of a validated stability-indicating HPLC method,” Acta Chromatographica, vol. 23, no. 2, pp. 215–234, 2011.

N. Fukutsu, T. Kawasaki, K. Saito, and H. Nakazawa, “Application of high-performance liquid chromatography hyphenated techniques for identification of degradation products of cefpodoxime proxetil,” Journal of Chromatography A, vol. 1129, no. 2, pp. 153–159, 2006.

K. Stoeckel, W. Hofheinz, J. P. Laneury, P. Duchene, S. Shedlofsky, and R. A. Blouin, “Stability of cephalosporin prodrug esters in human intestinal juice: implications for oral bioavailability,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 10, pp. 2602–2606, 1998.

M.-J. Wang, W.-B. Zou, J. Xue, and C.-Q. Hu, “Comparison of three RP-HPLC methods for analysis of cefpodoxime proxetil and related substances,” Chromatographia, vol. 65, no. 1-2, pp. 69–75, 2007.

P. Jain, A. Chaudhari, A. Bang, and S. Surana, “Validated stability-indicating high-performance thin-layer chromatographic method for estimation of cefpodoxime proxetil in bulk and in pharmaceutical formulation according to International conference on harmonization guidelines,” Journal of Pharmacy and Bioallied Sciences, vol. 4, no. 2, pp. 101–106, 2012.

S. I. Bhoir, P. V. Gaikwad, L. S. Parab, R. N. Shringarpure, S. S. Savant, and P. J. Verma, “RP-HPLC method development and validation for the simultaneous estimation of satranidazole and ofloxacin in pharmaceutical dosage form,” Journal of Chromatographic Science, vol. 49, no. 1, pp. 84–87, 2011.